Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2013The Journal of Clinical Endocrinology & MetabolismOpen Access

Potential Utility of Rituximab for Graves' Orbitopathy

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMario SalviFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoGVGuia VannucchiIRCCS Istituto Auxologico ItalianoPBPaolo Beck‐PeccozUniversity of Milan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Salvi et al. (2013) studied this question.

synapsesocial.com/papers/6a7100e526a7f98052dd710chttps://doi.org/10.1210/jc.2013-1804
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The effect of B cell depletion therapy on anti‐ TSH receptor antibodies and clinical outcome in glucocorticoid‐refractory Graves' orbitopathy2013 · 79 citations
  2. 2Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment2007 · 170 citations
  3. 3Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study2007 · 267 citations
  4. 4B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism2011 · 28 citations